Document:

Private Agreement

 

With this Private Agreement, having full legal effect between:

 

		1.	RIPA HOTEL & RESORT S.R.L., a company with registered office in Rome, Viale Bruno Buozzi
83, having tax code / VAT No. and registration No. in Rome's Business Registry 09838171008, in the person of its legal representative
Mr. Federico COLIZZI, born in Rome on 07/04/1957, having tax code CLZFRC57D07H501O, and the same legal address as the company’s
registered office, hereinafter also referred to as the Lessor.

 

and

 

		2.	KU HOTELS S.R.L., a company with registered office in Rome, Via Luigi Gianniti 21, having
tax code / VAT No. and registration No. in Rome's Business Registry 10260231005, in the person of its legal representative Mrs.
Martina TARRONI, born in Rome on 19/07/1982, having tax code TRRMTN82L59H501T, and the same legal address as the company’s
registered office, hereinafter also referred to as the Tenant.

 

Whereas:

 

		•	On 24/02/2009, by way of a private agreement registered by Notary Ferdinando Misiti, with office
in Rome – Inventory No.8905 Collection No 4740 as registered on 05/03/2009, with the Roma 2 Inland Revenue Agency under No.
7496 Series IT, such agreement being understood to be fully cited and approved herein, the Lessor RIPA HOTEL & RESORT SRL leased
to the Tenant KU HOTELS SRL the company division it holds title to, which runs the hotel complex (including bar, restaurant and
disco) known as "RIPA HOTEL" such business activity being carried out in the building located in Rome, Via degli Orti
di Trastevere 3;

 

		•	On 24/02/2009, by way of a private agreement registered electronically on 04/03/2009, the Lessor
company RIPA HOTEL & RESORT SRL, leased to the Tenant company KU HOTELS SRL the building inside which the aforementioned activity
is carried out, which is identified as: the entire building (category D/2) meant for hotel use, located in Rome, Via degli Orti
di Trastevere 3, comprised of 9 (nine) floors above ground for a total surface of approximately 17,000 covered square meters, identified
in Rome‘s Land Registry under sheet 449, parcel 204, sub. 200.

 

		•	The annual lease fees agreed were the following:

 

		Ø	1,260,000.00 Euros plus VAT for the business lease

		Ø	1,800,000.00 Euros plus VAT for the property lease

 

		•	The general financial crisis our Country is going through, particularly the difficulties encountered
by the hotel industry during the last 18/24 months have made it hard and problematic for the Tenant to fulfill the commitment initially
undertaken with the Lessor therefore, upon request of the Tenant, KU HOTELS SRL and RIPA HOTEL &. RESORT S.R.L. have made the
decision to renegotiate the aforementioned fees by 31/01/2013 by drafting new lease agreements and/or modifying some of the terms
that had been initially agreed.

 

    	 

    	 

    

 

		•	The parties already agree on the amounts of the new fees,
that shall be as follows:

 

		Ø	For the property lease, price has been renegotiated as follows:

 

		o	For the 2013-2014 two-year period: 1,800,000.00 (one million, eight hundred thousand/00) Euros plus VAT;

 

		o	For the 2015-2016 two-year period: 2,000,000.00 (two million/00) Euros plus VAT;

 

		o	As of 04/01/2017: 2,400,000.00 (two millions, four hundred thousand/00) Euros plus VAT.

 

		Ø	For the business lease, price has been renegotiated as follows

 

		o	For the 2013-2014 two-year period: 240,000.00 (two hundred and forty thousand/00) Euros plus VAT.

 

		o	For the 2015-2016 two-year period: 360,000.00 (three hundred and sixty thousand/00) Euros plus VAT.

 

		o	As of 04/01/2017 480,000.00 (four hundred and eighty thousand/00) Euros plus VAT.

 

		•	The Tenant has so far carried out a number of extraordinary
maintenance interventions on the leased property, made necessary by ordinary wear and tear of time and the need for the property
and the business to comply with the new provisions that have come into force in the meantime;

 

		•	The works carried out so far by KU HOTELS SRL, as confirmed by surveys and invoices are estimated
to amount to 800,000.00 Euros plus VAT;

 

		•	The debt of the Tenant company KU HOTELS SRL towards the Lessor company RIPA HOTEL & RESORT
SRL for lease fees installments which have fallen due and remain unpaid amounts to 3,557,759.65 Euros to date, including VAT.

 

		•	There is an evident need for continuous extraordinary maintenance to be carried out on the property
and by law or pursuant to the relevant agreements the relevant costs should be borne by the Lessor company.

 

		•	Considering the above, the parties have expressed their interest in defining the mutual credit and debt positions and reach
an agreement.

 

    	 

    	 

    

 

NOW, THEREFORE

 

The parties as represented above agree as
follows:

 

Art. 1

 

The preamble is an integral part and a covenant of
this agreement.

 

Art. 2

 

The party mutually agree as follows:
On 30/12/2012 the debt of the Tenant company KU HOTEL SRL to the Lessor company RIPA HOTEL & RESORT SRL, amounting to 3,557,759.65
Euros including VAT for lease fee installments which have fallen due and remain unpaid is considered settled through the procedure
indicated below:

 

		•	800,000.00 Euros plus VAT will be offset by the cost of works carried out so far by the Tenant
company, such works suitably documented, accepted by the Lessor company and charged to the latter via a regular invoice issued
by the Tenant company KU HOTELS SRL;

 

		•	89,759.65 Euros are to be paid by 31/03/2013, in line with the payment terms adopted so far.

 

		•	With regard to the remaining 2,500,000.00 Euros, the Parties agree that for the next nine years
the extraordinary maintenance interventions shall be carried out by the Tenant company KU HOTEL SRL upon initiative of the Lessor
company and under the guide and direction of the latter. The cost of the works to be carried out every year shall be at least 277,777.00
Euros including VAT. At the end of each financial year, the Tenant company shall issue a regular invoice to the Lessor company
for the amount of works suitably carried out, documented and accepted.

Art. 3

 

Failure of the Tenant company
to fulfill the commitments undertaken, whether for one or more than one financial year, shall result in the termination of this
agreement ipso facto and require the immediate payment of the residual debt to the Lessor company.

Art. 4

 

The directors of the two companies undertake to enter
this settlement into the accounting books today.

 

    	 

    	 

    

 

Read, approved and undersigned. Rome, March 10, 2013

 

	The Lessor	The Tenant
	/s/ Federico Colizzi	/s/ Martina TarroniSUPPLY AGREEMENT

 

THIS SUPPLY AGREEMENT (the “Agreement”)
is made and entered into as of the 15th day of February, 2012, between ProUroCare Medical Inc. (“PUC”), a Nevada corporation,
and Pressure Profile Systems, Inc. (“PPS”), a California corporation.

 

WITNESSETH

 

WHEREAS, PPS is the designer, manufacturer
and provider of Medical Products; and

 

WHEREAS, PUC is desirous of purchasing certain
of these Medical Products from PPS;

 

WHEREAS, the parties desire to establish
the terms and conditions which will apply to PUC’s purchase of such Medical Products from PPS.

 

NOW, THEREFORE, in consideration of the
representations, warranties, covenants and agreements contained herein, and for other valuable consideration, the receipt and adequacy
which is hereby acknowledged, the parties mutually agree as follows:

 

ARTICLE 1

DEFINITIONS

 

1.1)     Specific Definitions. As used in this Agreement,
the following terms shall have the meanings set forth or referenced below:

 

“Agreement” means this Agreement and all exhibits
and addendum hereto.

 

“Confidential Information” means know-how, trade
secrets, and unpublished information disclosed (whether before or during the term of this Agreement) by one of the parties (the
“disclosing party”) to the other party (the “receiving party”) or generated under this Agreement, excluding
information which:

 

		(a)	was already in the possession of receiving party (on
a non-confidential basis and without limitations on the use thereof) prior to its receipt from the disclosing party (provided
that the receiving party is able to provide the disclosing party with reasonable documentary proof thereof);

 

		(b)	is or becomes part of the public domain by reason of
acts not attributable to the receiving party;

 

		(c)	is or becomes available to receiving party from a source
other than the disclosing party which source, to the best of receiving party's knowledge, has rightfully obtained such information
and has no obligation of non-disclosure or confidentiality to the disclosure party with respect thereto;

 

    	1

    	 

    

 

		(d)	is made available by the disclosing party to a third
party unaffiliated with the disclosing party on an unrestricted basis;

 

		(e)	has been independently developed by the receiving party
without breach of this Agreement or use of any Confidential Information of the other party; or

 

		(f)	has been or must be publicly disclosed by reason of legal,
accounting or regulatory requirements beyond the reasonable control, and despite the reasonable efforts of the receiving party.

 

All Confidential Information disclosed by
one party to the other under this Agreement shall be in writing and bear a legend "Company Proprietary," "Company
Confidential" or words of similar import or, if disclosed in any manner other than writing, shall be preceded by an oral statement
indicating that the information is Company proprietary or confidential, and shall be followed by transmittal of a reasonably detailed
written summary of the information provided to the receiving party with identification as Confidential Information designated as
above within thirty (30) days.

 

“FDA” means the United States Food & Drug Administration.

 

“GMP” means Good Manufacturing Practices as defined
and specified in FDA’s quality system regulations applicable to medical devices, 21 CFR Part 820.

 

“Sensors” means and consists of two separate tactile
sensor arrays; one being a rectangular array utilized at the distal portion of the PUC probe (the “Distal Sensor”)
and the other being a circumferential array utilized at the proximal portion of the probe (the “Proximal Sensor”).
The specifications of such Sensors is set forth in Exhibit 1.

 

“Probe” means and consists of the Distal Sensor
and Proximal Sensor plus an orientation sensor, cabling, plastic casing and other components needed to make the Probe clinically
usable in the PMI System of PUC. The specifications of such Probe are set forth in Exhibit 1.

 

“Specifications” means the specifications for the
Probes and Sensors as set forth in Exhibit 1, as may be amended from time to time hereafter by agreement of the parties hereto.

 

“PMI System” means the PMI System specified in Exhibit
4.

 

“Medical Products” means and includes the Probes
and Sensors as such terms are defined and used herein.

 

“Biannual Capacity Forecast” means and consists
of the Sensor production forecast specified in Addendum 2, Paragraph 2a.

 

“Licensed Intellectual Property” means and includes
all patents, know-how and trade secrets owned, controlled, or licensed to PPS, now or in the future, relating in any way to the
Medical Products.

 

    	2

    	 

    

 

1.2)     Other
Terms. Other Terms may be defined elsewhere in the text of this Agreement and shall have the meaning indicated throughout this
Agreement.

 

1.3)     Other
Definitional Provisions.

 

(a) The words “hereof”, “herein”,
“hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not
to any particular provision in this Agreement,

 

(b) the terms defined in the singular shall
have a comparable meaning when used in the plural and vice versa,

 

(c) references to an Exhibit” or “Addendum”
are, unless otherwise specified, to one of the Exhibits or Addendums attached to or referenced in this Agreement and references
to an “Article” or a “Paragraph” are, unless otherwise specified, to one of the Articles or Paragraphs
of this Agreement,

 

(d) the term “person” includes
any individual partnership, joint venture, corporation, trust, unincorporated organization or government or any department or agency
thereof,

 

(e) the term “dollars” or “$”
shall refer to the currency of the United States of America.

 

ARTICLE 2

GENERAL OBLIGATIONS

 

2.1)      Manufacture
and Supply of Medical Products. PPS shall use all reasonable efforts to supply Medical Products in the quantities ordered by
PUC, in accordance with the applicable Specifications then in effect for such Medical Products and with purchase orders issued
under Paragraphs 3.1 and 7.1. The Medical Products shall be provided to PUC in packaging substantially equivalent to that which,
as of the date hereof, has customarily been used for the Medical Products or in such other packaging as the parties may agree.

 

2.2)      Compliance
with Laws and Regulations. PPS shall be responsible for compliance with present and future applicable statutes, laws, ordinances
and regulations of the national, federal, state and local governments now or hereinafter in effect relating to its manufacture
of Medical Products. Without limitation of the foregoing, PPS represents and warrants to PUC that all Medical Products sold and
delivered to PUC under this Agreement will have been manufactured in accordance with FDA GMP’s and all other applicable manufacturing
requirements and that continually during the term of this Agreement, no Medical Products delivered by PPS to PUC shall be adulterated
or misbranded at the time of delivery within the meaning of the U.S. Food, Drug & Cosmetic Act and regulations thereunder.
PPS shall cause PUC’s regulatory personnel to be provided with reasonable access, from time to time, to the facilities and
records of PPS for the purpose of confirming PPS’s compliance with any applicable FDA GMP’s and all other applicable
requirements. PPS labor costs to support PUC in their compliance reviews shall be billed at PPS’s support hourly rates set
forth in Addendum 1.

 

    	3

    	 

    

 

2.3)     Mutual
Representations and Warranties. Each party hereby represents and warrants to the other Party as follows:

 

(a)       Due
Authorization. Such Party has taken all necessary action on its part to authorize the execution and delivery of this Agreement
and the performance of its obligations hereunder.

 

(b)       Enforcement
of Obligations. This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid,
binding obligation, enforceable against such Party in accordance with its terms.

 

(c)       No
conflict. The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder do not
conflict with, or constitute a default or require any consent under, any contractual obligations of such Party to any third party.

 

2.4)      Manufacturing
Warranty. PPS warrants to PUC that it has or will obtain the capacity to fulfill the Biannual Capacity Forecast and that all
Medical Products supplied hereunder shall: (a) substantially conform to the applicable Specifications at the time of delivery to
a common carrier; and (b) be manufactured in substantial compliance with FDA GMP’s. Notwithstanding anything to the contrary
in this Agreement, PPS’s sole liability and PUC’s sole remedy for breach of the foregoing warranty shall be limited
to the actions and procedures set forth in Articles 6 and 10.

 

ARTICLE 3

SUPPLY OF PROBES

 

3.1)      Purchase
Orders. PUC shall submit purchase orders for the Probes to PPS in writing, whether by mail, telecopier, telecopy, telegram,
email or otherwise which shall, at a minimum, set forth the numbers, quantities, delivery dates and shipping instructions and shipping
addresses for all ordered Probes. All orders shall be subject to acceptance in accordance with the terms of this Agreement by PPS
at its office. Each purchase order shall, upon acceptance by PPS, give rise to a contract between PUC and PPS for the sale of Probes
ordered and shall be subject to and governed by the terms of this Agreement. The terms and conditions of this Agreement shall so
govern and supersede any additional or contrary terms set forth in PUC’s purchase order or any PPS acceptance, confirmation,
invoice, or other document unless duly signed by an officer of PUC and an officer of PPS expressly stating and identifying which
additional or contrary terms shall supersede the terms and conditions of this Agreement. All purchase orders shall be submitted
at least thirty (30) days in advance of the earliest scheduled delivery date for such order.

 

    	4

    	 

    

 

3.2)      Modification
and Cancellation of Purchase Orders. Mutually agreed change orders to any purchase order issued pursuant to Paragraph 3.1 above
shall be subject to all provisions of this Agreement, whether or not the change order so states. Any purchase order issued pursuant
to Paragraph 3.1 above may be cancelled by PUC at no cost or obligation to PUC as to any Probe which is not delivered within thirty
(30) days of the delivery date requested by PUC, and any such cancellation shall not limit or affect any other contract remedies
available to PUC with respect thereto. Any such cancellation by PUC shall be by written notice to PPS given within fifteen (15)
business days after such thirtieth (30th) day.

 

3.3)      PUC’s
Forecasts. PUC agrees to provide PPS promptly upon execution of this Agreement, with a six (6) month forecast indicating PUC’s
forecast purchases of Probes during the six (6) month period following the date of this Agreement. Such forecasts will be updated
by PUC on a monthly basis for a rolling successive six (6) month period; such updated forecasts must be received by PPS no later
than ten (10) days prior to the first day of each succeeding six (6) month period. Such rolling forecasts by PUC shall be used
for purposes of facilitating lead times required by certain of PPS’s suppliers and for scheduling manufacture at PPS’s
facilities, but shall not be legally binding on PUC except as follows:

 

a)      PUC shall
be obligated to issue purchase orders pursuant to Paragraph 3.1 for the quantity of probes set forth in such six (6) month rolling
forecast with the first month’s purchases being firm (i.e., not subject to deferral or acceleration) and the purchase order
for the second month’s purchases being able to be deferred or accelerated by PUC up to fifteen percent (15%) with the third
month’s purchases being able to be deferred or accelerated by PUC up to twenty-five percent (25%);

 

b)      PUC shall
be obligated to pay i) the full purchase price, ii) fifty percent (50%) of the purchase price, and iii) twenty five percent (25%)
of the purchase price for cancelling purchase orders for Probes ordered for delivery during the first, second and third month respectively
that such six (6) month rolling forecast is in effect. There shall be no cancellation charge for cancellation of purchase orders
in the fourth through the sixth months.

 

3.4)      Delivery
Terms. All deliveries of Probes shall be FOB PPS’s manufacturing facility located at 5757 Century Boulevard, Suite 600,
Los Angeles, California 90045. All risk of damage to or loss or delay of Probes shall pass to PUC, upon their delivery at the aforesaid
FOB point.

 

3.5)      Product
Changes. PPS shall not, without PUC’s prior written consent, alter the Specifications set forth in Exhibit 1 for Probes.

 

ARTICLE 4

PRICES AND PAYMENT FOR PROBES

 

4.1)      Prices
During the Term of this Agreement. The Purchase Prices per Probe to PUC under this Agreement shall be as set forth in Exhibit
2.

 

4.2)      Payment
Terms. Payments made by PUC for Probes purchased hereunder shall be due and payable in full within thirty (30) days after the
date of shipment by PPS.

 

    	5

    	 

    

 

ARTICLE 5

INSPECTION AND WARRANTY OF PROBES

 

5.1)      Inspection
of Probes. PUC shall conduct any incoming inspection tests not later than twenty (20) business days after the date of receipt
of such shipment at the shipping destination. Any Probe not rejected by PUC by written notice to PPS within such period shall be
deemed accepted, with the exception of latent defects not readily observable by PUC. In the event of any shortage, damage or discrepancy
in or to a shipment of Probes or in the event any Probes fail to comply with the then current Specifications for Probes, PUC shall
report the same to PPS and furnish such written evidence or other documentation as PPS reasonably may deem appropriate within such
twenty (20) business day period. If the substantiating evidence delivered by PUC indicates that such shortage, damage or discrepancy
or non-conformity with Specifications existed at the time of delivery of the Probes at the F.O.B. point, PUC may return the Probes
to PPS at PPS’s expense, and at PUC's request PPS shall use all reasonable efforts to deliver promptly replacement Probes
to PUC in accordance with the delivery procedures set forth herein.

 

5.2)      Warranty.
PPS warrants to PUC and to PUC's customers that Probes sold by PPS when delivered at the F.O.B. point meet the Specifications set
forth in Exhibit 1 and shall be free from defects in materials and workmanship. Without limitation of the foregoing, PPS shall
have no obligation in the event that:

 

		(i)	repair or replacement of any Probe shall have been required
through normal wear and tear or necessitated in whole or in part by catastrophe or the fault or negligence of PUC;

 

		(ii)	the infringement or defect complained of is caused by
PUC’s modification of the Probe in any manner;

 

		(iii)	the Probe shall have been lost, damaged, destroyed during
shipment to PUC;

 

		(iv)	the Probe shall not have been used or maintained in accordance
with PPS’s then applicable technical instructions for use, or its operating and/or maintenance manuals; or

 

		(v)	the duration from the date the Probes are clinically
used exceeds one year.

 

5.3)      Limited
Warranty. THE WARRANTIES SET FORTH ABOVE ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WHICH ARE HEREBY DISCLAIMED
AND EXCLUDED BY PPS, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE,
EXCEPT PPS SHALL ALSO PROVIDE WITH RESPECT TO AN ORDER OF MEDICAL PRODUCT SUCH OTHER WARRANTIES, IF ANY, AS PPS CUSTOMARILY PROVIDED
TO ITS CUSTOMERS OR END-USERS OF THE MEDICAL PRODUCTS IMMEDIATELY PRECEDING THE DATE OF THIS AGREEMENT. IN NO EVENT SHALL PPS’S
LIABILITY OF ANY KIND UNDER THIS AGREEMENT INCLUDE ANY PUNITIVE, PRESUMPTIVE, SPECIAL, EXEMPLARY, CONTINGENT, SPECULATIVE, INDIRECT,
INCIDENTAL OR CONSEQUENTIAL LOSSES OR DAMAGES, EVEN IF PPS SHALL HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH POTENTIAL LOSSES
OR DAMAGES.

 

    	6

    	 

    

 

ARTICLE 6

RIGHT TO MANUFACTURE PROBES

 

6.1)      Failure
to Deliver Probes. In the event PPS fails to deliver Probes according to purchase orders placed by PUC under Paragraph 3.1
that meet Specification and PPS is unable or unwilling to cure such failure within three (3) months, PUC may purchase Probes from
a third party or may itself manufacture Probes. This right to purchase Probes from a third party or itself manufacture Probes shall
for the purposes herein be deemed to be a “Right to Manufacture Probes”.

 

6.2)      Ability
to Deliver Probes. In the event PPS is able and willing to fulfill purchase orders for Probes placed by PUC that meet Specifications,
PUC may, nonetheless, at its option, upon six (6) months’ notice invoke its Right to Manufacture Probes.

 

6.3)      Transfer
of Ability to Manufacture. In the event PUC invokes its Right to Manufacture Probes under Paragraph 6.1 or 6.2 above, PPS agrees
to use best efforts to assist PUC and/or the applicable third party to successfully transfer the ability to assemble and manufacture
Probes. PUC shall pay PPS its support hourly rates per Addendum 1 for providing such assistance plus all incurred and appropriate
G&A and facilities (based on employee heads or space utilization expenses).

 

6.4)      License.
PPS hereby grants PUC a fully paid up, nonexclusive , sublicensible, worldwide license to the Licensed Intellectual Property to
make, have made, use, distribute, sell, or offer for sale, have sold, import, or otherwise commercialize Probes, excluding the
Sensors, during the term of this Agreement, in the event that PUC exercises its Right to Manufacture Probes. Such license shall
not become effective unless and until the occurrence of the Right to Manufacture Probes.

 

ARTICLE 7

SUPPLY OF SENSORS

 

7.1)      Purchase
Orders. PUC shall submit purchase orders for the Sensors to PPS in writing, whether by mail, telecopier, telecopy, telegram,
email or otherwise which shall, at a minimum, set forth the numbers, quantities, delivery dates and shipping instructions and shipping
addresses for all ordered Sensors. All orders shall be subject to acceptance in accordance with the terms of this Agreement by
PPS at its office. Each purchase order shall, upon acceptance by PPS, give rise to a contract between PUC and PPS for the sale
of Sensors ordered and shall be subject to and governed by the terms of this Agreement. The terms and conditions of this Agreement
shall so govern and supersede any additional or contrary terms set forth in PUC’s purchase order or any PPS acceptance, confirmation,
invoice, or other document unless duly signed by an officer of PUC and an officer of PPS expressly stating and identifying which
additional or contrary terms shall supersede the terms and conditions of this Agreement. All purchase orders shall be submitted
at least thirty (30) days in advance of the earliest scheduled delivery date for such order.

 

    	7

    	 

    

 

7.2)      Modification
and Cancellation of Purchase Orders. Mutually agreed change orders to any purchase order issued pursuant to Paragraph 7.1 above
shall be subject to all provisions of this Agreement, whether or not the change order so states. Any purchase order issued pursuant
to Paragraph 7.1 above may be cancelled by PUC at no cost or obligation to PUC as to any Sensor which is not delivered within thirty
(30) days of the delivery date requested by PUC, and any such cancellation shall not limit or affect any other contract remedies
available to PUC with respect thereto. Any such cancellation by PUC shall be by written notice to PPS given within fifteen (15)
business days after such thirtieth (30th) day.

 

7.3)      PUC’s
Forecasts. PUC agrees to provide PPS promptly upon execution of this Agreement, with a six (6) month forecast indicating PUC’s
forecast purchases of Sensors during the six (6) month period following the date of this Agreement. Such forecasts will be updated
by PUC on a monthly basis for a rolling successive six (6) month period; such updated forecasts must be received by PPS no later
than ten (10) days prior to the first day of each succeeding six (6) month period. Such rolling forecasts by PUC shall be used
for purposes of facilitating lead times required by certain of PPS’s suppliers and for scheduling manufacture at PPS’s
facilities, but shall not be legally binding on PUC except as follows:

 

a)      PUC shall
be obligated to issue purchase orders pursuant to Paragraph 3.1 for the quantity of probes set forth in such six (6) month rolling
forecast with the first month’s purchases being firm (i.e., not subject to deferral or acceleration) and the purchase order
for the second month’s purchases being able to be deferred or accelerated up to twenty percent (20%) with the third month’s
purchases being able to be deferred or accelerated up to thirty percent (30%);

 

b)      PUC shall
be obligated to pay i) the full purchase price, ii) fifty percent (50%) of the purchase price, and iii) twenty five percent (25%)
of the purchase price for cancelling purchase orders for Sensors ordered for delivery during the first, second and third month
respectively that such six (6) month rolling forecast is in effect. There shall be no cancellation charges for cancellation of
purchase orders in the fourth through the sixth months.

 

7.4)      Delivery
Terms. All deliveries of Sensors shall be FOB PPS’s manufacturing facility located at 5757 Century Boulevard, Suite 600,
Los Angeles, California 90045. All risk of damage to or loss or delay of Sensors shall pass to PUC, upon their delivery at the
aforesaid FOB point.

 

7.5)      Product
Changes. PPS shall not, without PUC’s prior written consent, alter the Specifications set forth in Exhibit 1 for Sensors.

 

    	8

    	 

    

 

ARTICLE 8

PRICES AND PAYMENT FOR SENSORS

 

8.1)      Prices
During the Term of this Agreement. The Purchase Prices per Sensor to PUC under this Agreement shall be as set forth in Exhibit
3.

 

8.2)      Payment
Terms. Payments made by PUC for Sensors purchased hereunder shall be due and payable in full within thirty (30) days after
the date of shipment by PPS.

 

ARTICLE 9

INSPECTION AND WARRANTY OF SENSORS

 

9.1)      Inspection
of Sensors. PUC shall conduct any incoming inspection tests not later than twenty (20) business days after the date of receipt
of such shipment at the shipping destination. Any Sensor not rejected by PUC by written notice to PPS within such period shall
be deemed accepted, with the exception of latent defects not readily observable by PUC. In the event of any shortage, damage or
discrepancy in or to a shipment of Sensors or in the event any Sensors fail to comply with the then current Specifications for
the Sensor, PUC shall report the same to PPS and furnish such written evidence or other documentation as PPS reasonably may deem
appropriate within such twenty (20) business day period. If the substantiating evidence delivered by PUC indicates that such shortage,
damage or discrepancy or non-conformity with Specifications existed at the time of delivery of the Sensors at the F.O.B. point,
PUC may return the Sensors to PPS at PPS’s expense, and at PUC's request PPS shall use all reasonable efforts to deliver
promptly replacement Sensors to PUC in accordance with the delivery procedures set forth herein.

 

9.2)      Warranty.
PPS warrants to PUC and to PUC's customers that Sensors sold by PPS when delivered at the F.O.B. point meet the Specifications
set forth in Exhibit 1 and shall be free from defects in materials and workmanship. Without limitation of the foregoing, PPS shall
have no obligation in the event that:

 

		(i)	repair or replacement of any Sensor shall have been required
through normal wear and tear or necessitated in whole or in part by catastrophe or the fault or negligence of PUC;

 

		(ii)	the infringement or defect complained of is caused by
PUC’s modification of the Sensor in any manner;

 

		(iii)	the Sensor shall have been lost, damaged, destroyed during
shipment to PUC;

 

		(iv)	the Senor shall not have been used or maintained in accordance
with PPS’s then applicable technical instructions for use, or its operating and/or maintenance manuals; or

 

		(v)	the duration from the date the Sensors are clinically
used exceeds one year.

 

    	9

    	 

    

 

9.3)        Limited
Warranty. THE WARRANTIES SET FORTH ABOVE ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WHICH ARE HEREBY DISCLAIMED
AND EXCLUDED BY PPS, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE,
EXCEPT PPS SHALL ALSO PROVIDE WITH RESPECT TO AN ORDER OF MEDICAL PRODUCT SUCH OTHER WARRANTIES, IF ANY, AS PPS CUSTOMARILY PROVIDED
TO ITS CUSTOMERS OR END-USERS OF THE MEDICAL PRODUCTS IMMEDIATELY PRECEDING THE DATE OF THIS AGREEMENT. IN NO EVENT SHALL PPS’S
LIABILITY OF ANY KIND UNDER THIS AGREEMENT INCLUDE ANY PUNITIVE, PRESUMPTIVE, SPECIAL, EXEMPLARY, CONTINGENT, SPECULATIVE, INDIRECT,
INCIDENTAL OR CONSEQUENTIAL LOSSES OR DAMAGES, EVEN IF PPS SHALL HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH POTENTIAL LOSSES
OR DAMAGES.

 

ARTICLE 10

VARIOUS SENSOR RIGHTS

 

10.1)      Purchase
of Sensors. If PUC purchases Probes under and pursuant to Articles 3 – 6 above, then PUC would not issue purchase orders
for the purchase of Sensors under Article 7; i.e., PUC’s purchase of Sensors would be encompassed within its purchase of
Probes. However, should PUC exercise its Right to Manufacture Probes under Article 6 above, then Articles 7-10 shall be invoked
as specified herein.

 

10.2)      Factory
in a Factory Right. PUC shall have the right, at its option, to invoke a factory in a factory concept (the “Factory in
a Factory Right”) described in Addendum 2, at any time, irrespective of whether or not PPS is; 1) able and willing; or 2)
able and unwilling to provide Sensors that meet Specifications and fulfill purchase orders placed by PUC under Paragraph 7.1.
There should be no cost or charge to PUC for invoking this Factory in a Factory Right, except and to the extent specifically prescribed
in Addendum 2. PUC shall have the right to invoke this Factory in a Factory Right, at any time, upon thirty (30) days prior written
notice to PPS.

 

10.3)      Right
to Manufacture Sensors. Irrespective of whether or not the Factory in a Factory Right as specified in Paragraph 10.2 has been
invoked by PUC, in the event PPS is unable or unwilling to provide PUC with Sensors according to purchase orders placed by PUC
under Paragraph 7.1 that meet Specification and PPS is unable to cure such failure within three (3) months, then PUC shall have
the option to invoke the right to manufacture the sensors itself or to have a third party of its choosing manufacture such sensors
(the “Right to Manufacture Sensors”). There shall be no cost or charge to PUC for invoking this Right to Manufacture
Sensors, except and to the extent set forth in Paragraph 10.5. In the event that PPS is willing and able to provide sensors to
PUC according to purchase orders placed by PUC under Paragraph 7.1 that meet Specification, PUC may nonetheless, at its option,
upon six (6) months’ notice and the payment of One Million Five Hundred Thousand Dollars ($1,500,000.00) invoke this Right
to Manufacture Sensors itself or have a third party of its choosing manufacture such Sensors.

 

    	10

    	 

    

 

10.4)      License
Grant. Upon PUC exercising the Right to Manufacture Sensors outlined above in Paragraph 10.3 above, PPS shall provide and hereby
grants PUC an exclusive, sublicensible license within the prostate field of use (“Field of Use”) to all applicable
patents owned, controlled or licensed to PPS which could reasonably be considered to encompass the Sensors plus all applicable
trade secrets and other technical information relating to the Sensors (the “Sensor License”). The license royalty for
such Sensor License shall be Four Hundred Dollars ($400.00) per PMI System (the “License Royalty”) encompassing such
Sensors which is commercially sold or distributed for use by PUC. The License Royalty shall be due and payable only once per PMI
System sold or distributed for use by PUC irrespective of the number of Probes and/or Sensors that may be utilized with that PMI
System. (That is, in the event that a ProUroScan System utilizes multiple or disposable Probes, the license royalty shall be payable
once for each PMI System and not for each Probe utilized therewith.) The License Royalty shall be paid quarterly with such payment
being made within forty five (45) days of the end of each such calendar quarter. A royalty cap of Five Million Dollars ($5,000,000.00)
shall apply to this Sensor License. That is, once PUC has paid PPS Five Million Dollars ($5,000,000.00) in royalties under this
Paragraph 10.4, this Sensor License shall be deemed to be fully paid up and worldwide within the Field of Use.

 

10.5)      Technology
Transfer Fee. In the event that PUC invokes its Right to Manufacture Sensors as outlined in Paragraph 10.3 above, PUC shall
pay to PPS a Technology Transfer Fee (the “Technology Transfer Fee”) as follows:

 

One Million Five Hundred Thousand Dollars
($1,500,000.00) payable twenty five percent (25%) upon PUC’s notification that it is invoking the Right to Manufacture Sensors;
fifty percent (50%) upon successful transfer of the technology as demonstrated by the manufacturer of at least five (5) Sensors
which fully meet all applicable specifications; and twenty five percent (25%) upon commercial sale of the first ten (10) PMI Systems
encompassing the Sensors produced at the site to which the technology transfer was made.

 

However, in the event PPS elects to terminate
this Agreement, the Technology Transfer Fee shall be redued from One Million Five Hundred Thousand Dollars ($1,500,000.00) to One
Million Dollars ($1,000,000.00) with all other provisions of Paragraphs 10.5 and 10.6 remaining in full force and effect.

 

10.6)      Best
Efforts to Transfer Technology. The Technology Transfer Fee specified in Paragraph 10.5 above shall be considered to be payment
for PPS using its best efforts to transfer the technology and knowhow needed to manufacture Sensors to Specification under suitable
safeguards to protect PPS’s Confidential Information from third parties. Such transfer shall encompass providing Sensor Specifications
and manufacturing processes, tooling and methods applicable and/or needed to manufacture the Sensors to Specification plus training
of individuals selected by PUC on the art and/or science of manufacturing Sensors and access to current PPS suppliers, so that
the Sensors can be reliably and repeatedly produced to Specification. PUC shall, in addition to this Technology Transfer Fee pay
PPS its support hourly rate per Addendum 1 for supporting the transfer process plus all incurred and appropriate G&A and facilities
(based on employee heads or space utilization) expenses.

 

    	11

    	 

    

 

ARTICLE 11

TERMINATION

 

11.1)      Termination
by PUC. PUC shall have the right to terminate this Agreement at any time upon six (6) months’ notice at no cost or obligation
to it, except as follows:

 

		a)	In the event PUC has not exercised its Right to Manufacture Probes under Article 6 above, then PUC shall i) be obligated
to take delivery of and pay for all Probes included and encompassed in the then current six (6) month rolling forecast set forth
under Paragraph 3.3.

 

		b)	In the event PUC has exercised its Right to Manufacture Probes under Article 6 above, then PUC shall i) be obligated to take
delivery of and pay for all Sensors included and encompassed in the then current six (6) month rolling forecast set forth under
Paragraph 7.3 above, and ii) be deemed to have waived any and all rights it would otherwise have to defer or cancel purchase orders
submitted under Subparagraphs a) and b) of Paragraph 7.3.

 

11.2)      Termination
by PPS. PPS shall have the right to terminate this Agreement at anytime upon six (6) months’ notice at no cost or obligation
to it, except as follows:

 

To help bridge the gap until another
supplier of Medical Products can be secured, PPS shall be obligated to fulfill purchase orders for Medical Products submitted pursuant
to Paragraphs 3.1 or 7.1 up to one hundred twenty five (125%) of the then current six (6) month rolling forecast for such Medical
Products set forth in Paragraph 3.3 and 7.3, whichever is applicable; and

 

ARTICLE 12

MISCELLANEOUS

 

12.1)      Non-Disclosure.
Except as permitted or required for performance of its rights of duties under this Agreement, each party agrees (i) not to disclose
or use any Confidential Information of the other party obtained in connection with the performance of this Agreement, and (ii)
not to disclose or provide any of such Confidential Information of the other party to any third party and to take appropriate measures
to prevent any such disclosure by its present and future employees, officers, agents, subsidiaries, or consultants.

 

12.2)      Relationship.
This Agreement does not make either party the employee, agent or legal representative of the other for any purpose whatsoever.
Neither party is granted any right or authority to assume or to create any obligation or responsibility, express or implied, on
behalf of or in the name of the other party. In fulfilling its obligations pursuant to this Agreement, each party shall be acting
as an independent contractor.

 

    	12

    	 

    

 

12.3)      Assignment.
This Agreement shall be binding upon and inure to the benefit of the parties hereto and the successors or assigns of the parties
hereto; provided, that (i) the rights and obligations of PPS herein may not be assigned except to any person who succeeds to substantially
all of the assets and business of PPS, and (ii) the rights and obligations of PUC herein may not be assigned except to any person
who succeeds to substantially all of that portion of PUC's business to which this Agreement relates.

 

12.4)      Complete
Agreement. The Exhibits and Addendum to this Agreement shall be construed as an integral part of this Agreement to the same
extent as if they had been set forth verbatim herein. This Agreement and the Exhibits and Addendum hereto constitute the entire
agreement between the parties hereto with respect to the subject matter hereof and supersede all prior agreements whether written
or oral relating hereto.

 

12.5)      Governing
Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of California, including
all matters of construction, validity, performance and enforcement, without giving effect to principles of conflict of laws.

 

12.6)      Survival.
All of the representations, warranties, and covenants made in this Agreement, and all terms and provisions hereof intended to be
observed and performed by the parties after the termination hereof, shall survive such termination and continue thereafter in full
force and effect.

 

12.7)      Waiver,
Discharge, Amendment, Etc. The failure of any party hereto to enforce at any time any of the provisions of this Agreement shall
in no way be construed to be a waiver of any such provision, nor in any way to affect the validity of this Agreement or any part
thereof or the right of the party thereafter to enforce each and every such provision. No waiver of any breach of this Agreement
shall be held to be a waiver of any other or subsequent breach. Any amendment to this Agreement shall be in writing and signed
by the parties hereto.

 

12.8)      Counterparts.
This Agreement may be executed in any number of counterparts, each of which shall be deemed as original and all of which together
shall constitute one instrument.

 

12.9)      Titles
and Headings; Construction. The titles and headings to Sections and Paragraphs herein are inserted for the convenience of reference
only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. This Agreement shall be
construed without regard to any presumption or other rule requiring construction hereof against the party causing this Agreement
to be drafted.

 

12.10)    Benefit.
Nothing in this Agreement, expressed or implied, is intended to confer on any person other than the parties to this Agreement or
their respective successors or assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement.

 

    	13

    	 

    

 

12.11)    Notices. All notices or other communications
to a party required or permitted hereunder shall be deemed given if in writing and delivered personally or sent by telecopy (with
confirmation of transmission) or certified mail (return receipt requested) to such party at the following addresses (or at such
other addresses as shall be specified by like notice):

 

if to PUC to:

 

ProUroCare Medical Inc.

6440 Flying Cloud Drive, Suite 101

Eden Prairie, MN 55344

Attention: Richard C. Carlson

 

if to PPS to:

 

Pressure
Profile Systems, Inc.

5757 Century Boulevard, Suite 600

Los Angeles, California 90045

Attention: Jae Son

 

PUC or PPS may change their respective above-specified recipient
and/or mailing address by notice to the other party given in the manner herein prescribed. All notices shall be deemed given on
the day when actually delivered as provided above (if delivered personally or by telecopy) or on the day shown on the return receipt
(if delivered by mail).

 

12.12)  Illegality. In case any provision of this
Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall
not in any way be affected or impaired thereby.

 

12.13)  Dispute Resolution. Any dispute arising
out of or relating to this Agreement, including any alleged fraud in the inducement or any alleged breach hereof, shall be settled
in accordance with Addendum 3. The results of any arbitration proceedings shall be binding upon the parties hereto, and judgment
may entered upon the arbitration award in any court having jurisdiction thereof. Notwithstanding the foregoing, either party may
seek interim injunctive relief from any court of competent jurisdiction.

 

    	14

    	 

    

 

IN WITNESS WHEREOF, each of the parties
has caused this Supply Agreement to be executed in the manner appropriate to each, as of the date first above written.

 

	 	Pressure Profile Systems, Inc.
	 	 
	 	By	/s/Jae Son
	 	Its	CEO
	 	 	 
	 	PROUROCARE MEDICAL INC.
	 	 	 
	 	By	/s/Richard Carlson
	 	Its	CEO

 

    	15

    	 

    

 

EXHIBIT 1

 

SENSOR AND PROBE SPECIFICATIONS

 

Specifications for Probes.

 

[Stan: If we have product specs in a document, we
can just reference and append that document here.]

 

Specifications for Sensors.

 

[Stan: If we have product specs in a document, we
can just reference and append that document here.]

 

    	16

    	 

    

 

EXHIBIT 2

 

Purchase
price of Probes*

 

 

First 10 Probes $8,000.00

Next 20 Probes $7,400.00

Next 70 Probes $6,500.00

Additional Probes $6,000.00

 

_____________________________

 

*The specified pricing includes PPS directly
sourcing all the required Probe components and materials, with the exception of the orientation sensors. PUC shall have the option
to purchase the orientation sensors directly and supply them to PPS or have PPS purchase them and bill PUC at cost.

 

    	17

    	 

    

 

EXHIBIT 3

 

PURCHASE PRICE OF SENSORS

 

 

First 10 Sensors $4,000.00

Next 20 Sensors $3,500.00

Next 70 Sensors $3,000.00

Additional Sensors $2,800.00

 

    	18

    	 

    

 

EXHIBIT 4

 

SPECIFICATION OF PMI SYSTEM OF PUC

 

[Stan: We can include or reference the product manual
or other document containing Specifications for the ProUroScan System here.]

 

    	19

    	 

    

 

Addendum
1: PPS Support Hourly Rates

 

Tactile Sensor Technology Consulting: $280/hr.

 

Project Management/System Engineering: $200/hr.

 

Electrical Design & Firmware Engineering: $150/hr.

 

Software Engineering: $150/hr.

 

Technical Support: $150/hr.

 

Mechanical Design/Testing: $125/hr.

 

Production/Assembly: $90/hr.

 

    	20

    	 

    

 

Addendum
2: Factory in the Factory Right

 

1.          Provision
Summary

 

The Factory in the Factory Right aims to create a self-reliant,
reliable, dependable and FDA compliant production area and quality organization dedicated to ProUroCare Sensor manufacturing within
the PPS facilities located at 5757 Century Boulevard, Suite 600, Los Angeles, California 90045 (the “PPS Facilities”).

 

2.          Roles
and Responsibilities

 

		a)	ProUroCare will be responsible to provide PPS a Sensor production capacity forecast biannually in January and July of each
year (the “Biannual Capacity Forecast”). This Biannual Capacity Forecast will delineate the expected Sensor needs of
PUC for the next 12-24 months. Furthermore, this Biannual Capacity Forecast shall be totally separate and independent from the
PUC forecasts specified in Paragraph 7.3 and shall be used only for purposes of facilitating PUC’s marketing plans and PPS’s
manufacturing scheduling, but shall not obligate PUC to submit Purchase Orders for Sensors under Paragraph 7.1 in accordance therewith.

 

		b)	PPS is responsible for providing an adequate segregated manufacturing environment (“Segregated Environment”) for
the production of the Sensors in terms of production space, equipment, trained production operators, processes, tooling, production
and test equipment, material receiving, inspection and stores capabilities as, if, and when needed to meet the Biannual Capacity
Forecast. If PUC does not concur that the Segregated Environment proposed by PPS is adequate, the parties agree to negotiate in
good faith to reach such mutually acceptable Segregated Environment.

 

		c)	PPS is responsible to provide all related support for the Segregated Environment to include IT, facility and equipment maintenance,
administrative activities, etc., as well as the required facility utilities, insurance environmental certificates, etc., required
to keep the Segregated Environment in service.

 

		d)	ProUroCare shall have the right to provide and maintain an FDA compliant “Quality System” within the Segregated
Environment within the PPS Facilities and PPS shall use best efforts to comply with the requirements of such “Quality System”.
As used here, the term “Quality System” means a quality system which meets and complies fully with the requirements
set for a Quality System in 21 CFR 820.

 

    	21

    	 

    

 

		e)	ProUroCare has the option to hire and locate a ProUroCare Production Manager/Engineer and/or a Quality Manager/Engineer within
the Segregated Environment within the PPS Facilities. Such individual(s) will be employees of ProUroCare and all related costs
including appropriate allocation of G&A and facility costs (based on employee heads or space utilization) will be the responsibility
of ProUroCare. They shall have access to all Sensor manufacturing activities, processes, records, reports, technologies and know-how
under suitable safeguards to protect PPS’s Confidential Information from third parties.

 

		f)	PPS labor costs to train PUC employees per section e
of this Paragraph 2 and to support PUC in maintaining their own FDA compliant “Quality System” per section d of this
Paragraph 2 shall be billed at the PPS’s support hourly rates set forth in Addendum 1.

 

		g)	The role of a Production Manager/Engineer will be primarily to identify recommended process and cycle time improvements as
well as cost reduction opportunities. If there are incremental investments required to implement such process and cycle time improvements
and cost reductions, the costs will be negotiated in good faith between the two parties.

 

		h)	The role of a Quality Manager/Engineer will be primarily to implement and maintain compliance to the ProUroCare “Quality
System”. If there are incremental costs associated with implementing and maintaining the Quality System, the costs will be
negotiated in good faith between the two parties.

 

    	22

    	 

    

 

ADDENDUM 3: DISPUTE RESOLUTION

 

1)          Negotiations.
If any dispute arises between PUC and PPS with respect to the Agreement or any alleged breach thereof, either party may, by written
notice to the other party, have such dispute referred to the individuals designated below or their successors for attempted resolution
by good faith negotiations within forty-five (45) days after such written notice is received. Such designated employees are as
follows:

 

For PPS – Jae Son

 

For PUC – Richard C. Carlson

 

Any settlement reached by the parties under this Section 1 shall
not be binding until reduced to writing and signed by the above-specified representatives of PPS and PUC. When reduced to writing,
such settlement agreement shall supersede all other agreements, written or oral, to the extent such agreements specifically pertain
to the matters so settled.

 

If the above-designated individuals are
unable to resolve such dispute within such forty-five (45) day period, any party may invoke the provisions of Section 2 below.

 

2)          Arbitration.
Any controversy or claim arising out of or relating to this Agreement or the validity, inducement or breach of this Agreement,
shall be settled by arbitration before a single arbitrator in accordance with the Commercial Arbitrator Rules of the American Arbitration
Association, and judgment upon the award may be entered in any court having jurisdiction thereof. The arbitrator shall be an attorney
specializing in business litigation who has at least 15 years of experience with a law firm of over 25 lawyers or was a judge of
a court of general jurisdiction. The arbitration shall be held in Minnesota and the arbitrator shall apply the substantive law
of Minnesota, except that the interpretation and enforcement of this arbitration provision shall be governed by the Federal Arbitration
Act. The arbitrator shall not award any party punitive damages.

 

    	23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]